# US 2017/0362225 A1 · Bicyclic compounds, compositions and medicinal applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362225 A1
- Document ID: US20170362225A1
- Status: Published application
- Kind: A1
- Application number: 15/541,875
- Filed: 2016-01-08
- Published: 2017-12-21
- Earliest claimed: 2015-01-08
- Assignees: Advinus Therapeutics Limited
- Applicants: Advinus Therapeutics Limited
- Inventors: Partha Mukhopadhyay; Yogesh Munot; Nadim Shaikh; Bheemashankar A. Kulkarni; Kasim Mookhtiar
- Web page: https://patentgrep.com/patent/US20170362225A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a class of substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them. The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (RORγ) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.

## Claims

### Claim 1

A compound represented by Formula I
their tautomers, polymorphs, stereoisomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof,
wherein,
Q represents a bicyclic group selected from the group consisting of
wherein ** represents point of attachment of T;
# represents point of attachment of Y;
each “” is independently a single or double bond;
U, V and W are independently selected from the group consisting of N, NR′, CR′ and CR′ R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R′ and R″ taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally have additional heteroatoms selected from the group consisting of O, N and S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
T and Y is selected from
a) T is a monocyclic or a bicyclic carbocyclic ring system which is saturated, unsaturated or partially unsaturated, and which is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is a group selected from the group consisting of —O—, —S(O)p—, —N(R7)—, —C(O)—, —C(S)— and —(CRaRb)—; or
b) T is a monocyclic or a bicyclic ring system which is saturated, unsaturated or partially unsaturated, and which and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, and is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is —C(O)— or —C(S)—;
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or
Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally have one or more additional heteroatoms selected from the group consisting of O, N and S;
X1, X2 and X3 are each independently selected from the group consisting of N and CR7;
Z is —C(O)— or —S(O)p—;
R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —NR7R8, —OR7, —S(O)pR7, —S(O)pNR7R8, —NR7S(O)pR8, —NR7C(O)R8, —OS(O)pR8, —NR7C(O)OR8, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7R8)nC(O)OR7, or when R4 or R5 are more than one, then 2 R4 or 2 R5 independently can form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated, and which optionally comprise one or more additional heteroatoms selected from the group consisting of O, N and S;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)nC(O)NR7R8, —S(O)pR7 and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloalkyl, perhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, and arylalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, aminocarbonyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl;
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R7 and R8 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from O, N or S, wherein said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
p=0-2; and
n=0-4.

### Claim 2 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, wherein
U, V and W are independently selected from the group consisting of N, NR′, CR′ and CR′R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R′ and R″ taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprise one or more additional heteroatoms selected from the group consisting of O, N and S, wherein said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
T and Y are defined as either:
a) T is a monocyclic or a bicyclic carbocyclic ring system which is saturated, unsaturated or partially unsaturated, which is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is a group selected from the group consisting of —O—, —S(O)p—, —N(R7)—, —C(O)—, —C(S)— and —(CRaRb)—; or
b) T is a monocyclic or a bicyclic ring system which is saturated, unsaturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, and is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is —C(O)— and or —C(S)—;
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or
Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
X1, X2 and X3 are each independently selected from the group consisting of N and CR7;
Z is —C(O)— or —S(O)p—;
R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —NR7R8, —OR7, —S(O)pR7, —S(O)pNR7R8, —NR7S(O)pR8, —NR7C(O)R8, —OS(O)pR8, —NR7C(O)OR8, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7Rb)nC(O)OR7; or when R4 or R5 are more than one, then any 2 R4 or 2 R5 independently, taken together can form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and which optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)nC(O)NR7R8, —S(O)pR7 and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6alkyl, haloalkyl, perhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, and arylalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, aminocarbonyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl;
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R7 and R8 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and which optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, wherein said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
p=0-2; and
n=0-4.

### Claim 3 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or pharmaceutically acceptable salts thereof, wherein
U, V and W are independently selected from the group consisting of N, NR′, CR′ and CR′R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R′ and R″ taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, wherein said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
T and Y are defined as either:
a) T is selected the group consisting of cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl and arylalkyl;
wherein cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl and arylalkyl are unsubstituted or substituted independently with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is selected from the group consisting of —O—, —S(O)p—, —N(R7)—, —C(O)—, —C(S)— and —(CRaRb)—; or
b) T is cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl;
wherein cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl are unsubstituted or substituted independently with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is —C(O)— and or —C(S)—;
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or
Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and which optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
X1, X2 and X3 are each independently selected from the group consisting of N and CR7;
Z is —C(O)— or —S(O)p—;
R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —NR7R8, —OR7, —S(O)pR7, —S(O)pNR7R8, —NR7S(O)pR8, —NR7C(O)R8, —OS(O)pR8, —NR7C(O)OR7, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7R8)nC(O)OR7; or when R4 or R5 are more than one, then any 2 R4 or 2 R5 independently, taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprise one or more additional heteroatoms selected from the group consisting of O, N and S;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)nC(O)NR7R8, —S(O)pR7 or and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloalkyl, perhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, and arylalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, aminocarbonyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl;
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R7 and R8 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and which optionally comprises one or more additional heteroatoms selected from O, N or S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
p=0-2; and
n=0-4.

### Claim 4 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, wherein
U, V and W are independently selected from the group consisting of N, NR′, CR′ and CR′R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R′ and R″ taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
T and Y are defined as either
a) T is cyclopropyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, or phenyl,
wherein T is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is a group selected from the group consisting of —O—, —S(O)p—, —N(R7)—, —C(O)—, —C(S)— and —(CRaRb)—; or
b) T is selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, pyridinyl, tetrahydropyridinyl, tetrahydropyranyl, piperazinyl, benzodiaxolyl, tetrahydroquinolinyl, morpholinyl, tetrahydronaphthyridinyl, tetrahydrothienopyridinyl, furanyl, pyridinyl, pyrimidinyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, indolyl, quinolinyl, isoquinolinyl and benzooxazolyl
wherein T is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is a group selected from the group consisting of —C(O)— and —C(S)—;
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or
Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
X1, X2 and X3 are each independently selected from the group consisting of N and CR7;
Z is —C(O)— or —S(O)p—;
R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —NR7R8, —OR7, —S(O)pR7, —S(O)pNR7R8, —NR7S(O)pR8, —NR7C(O)R8, —OS(O)pR8, —NR7C(O)OR8, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7R8)nC(O)OR7; or when R4 or R5 are more than one, then any 2 R4 or 2 R5 independently, taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprise one or more additional heteroatoms selected from the group consisting of O, N and S;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)pC(O)NR7R8, —S(O)pR7 and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloalkyl, perhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, and arylalkyl;
R6 is hydrogen, alkyl, haloalkyl, alkoxy, carboxy, aminocarbonyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R7 and R8 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, wherein said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
p=0-2; and
n=0-4.

### Claim 5 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, wherein
U, V and W are independently selected from the group consisting of N, NR′, CR′ and CR′R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R′ and R″ taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
T is cyclopropyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, phenyl, tetrahydrofuranyl, pyrrolidinyl, pyridinyl, tetrahydropyridinyl, tetrahydropyranyl, piperazinyl, benzodiaxolyl, tetrahydroquinolinyl, morpholinyl, tetrahydronaphthyridinyl, tetrahydrothienopyridinyl, furanyl, pyridinyl, pyrimidinyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, indolyl, quinolinyl, isoquinolinyl or benzooxazolyl
wherein T is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, nitro, cyano, —(CRaRb)mOR6, —(CRaRb)mSR6, —(CRaRb)mNR7R8, oxo, alkylsulfonyl, —(CRaRb)mCOOR6, —(CRaRb)mC(O)NR7R8, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
Y is selected from the group consisting of —O—, —S(O)p—, —N(R7)—, —C(O)—, —C(S)— and —(CRaRb)—;
Ra and Rb are independently selected from the group consisting of hydrogen, —OR7, halogen, haloalkyl, perhaloalkyl and alkyl; or
Ra and Rb taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
X1, X2 and X3 are each independently selected from N and CR7;
Z is —C(O)— or —S(O)p—;
R1, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —NR7R8, —OR7, —S(O)pR7, —S(O)pNR7R8, —NR7S(O)pR8, —NR7C(O)R8, —OS(O)pR8, —NR7C(O)OR8, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7R8)nC(O)OR7, or when R4 or R5 are more than one, then any 2 R4 or 2 R5 independently is optionally, taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprises one or more additional heteroatoms selected from the group consisting of O, N and S;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)nC(O)NR7R8, —S(O)pR7 and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, haloalkyl, perhaloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, aryl, and arylalkyl;
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, aminocarbonyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl, or
R7 and R8 taken together form a monocyclic or a bicyclic ring system which is saturated or partially unsaturated and optionally comprise one or more additional heteroatoms selected from O, N or S, said ring system is further optionally substituted with 1 to 4 substituents independently selected from the group consisting of halo, alkyl, haloalkyl, alkenyl, alkynyl, nitro, cyano, alkoxy, amino, oxo, alkylsulfonyl, carboxy, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
p=0-2; and
n=0-4.

### Claim 6 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, wherein
U, V and W are independently selected from the group consisting of CR′ and CR′R″;
G is CR′;
R′ and R″ are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl and cyano
T is cyclohexenyl, phenyl, pyridyl, or tetrahydropyridinyl;
Y is —C(O)—
X1, X2 and X3 are CR7;
Z is —C(O)—;
R1 R4 and R5 are independently selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy, amino, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, tetrazolyl, tetrazolylalkyl, mono, di or tri substituted haloalkyl, nitrile, nitro, oxo, —(CR7R8)nC(O)OR7, —(CR7R8)n(CO)NR7R8, —(CR7R8)nS(O)pNR7R8, —(CR7R8)nN(R7)C(O)R7, —(CR7R8)nOR7, —C(R7R8)nNR7R8, —C(R7R8)nCO(R7) and —S(O)pC(R7R8)nC(O)OR7;
wherein each substituent is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, cyano, alkoxy, —(CRaRb)nCOOR7, —(CRaRb)nNR7R8, —(CRaRb)nC(O)NR7R8, —S(O)pR7 and —SO3H.;
R2 and R3 are independently selected from the group consisting of halo, hydroxyl, cyano, C1-6 alkylhaloalkyl, and perhaloalkyl,
R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, carboxy, hydroxyl, cyano, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl,
p=0-2; and
n=0-4.

### Claim 7 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, which is
Ethyl 4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoate;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
methyl 4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-3-fluoro-benzoate;
methyl 4-[3-(2,6-difluorobenzoyl)indolizin-1-yl]-3-fluoro-benzoate;
ethyl 4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]benzoate;
methyl 4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-3,5-difluoro-benzoate;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-3,5-difluoro-benzoic acid;
5-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]pyridine-2-carboxylic acid;
methyl 4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-3-fluoro-benzoate;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-3-fluoro-benzoic acid;
methyl 4-[3-(2-chloro-6-methyl-benzoyl)indolizin-1-yl]-3-fluoro-benzoate;
ethyl 4-[3-(2-chloro-6-methyl-benzoyl)indolizin-1-yl]benzoate;
4-[3-(2-chloro-6-methyl-benzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2-chloro-6-methyl-benzoyl)indolizin-1-yl]benzoic acid;
methyl 4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]benzoic acid;
(2,6-dichlorophenyl)-[1-(4-methylsulfonylphenyl)indolizin-3-yl]methanone;
ethyl 4-[3-(2,6-dichlorobenzoyl)-8-fluoro-indolizin-1-yl]benzoate;
methyl 4-[3-(2,6-dichlorobenzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichlorobenzoyl)-8-fluoro-indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2-chloro-6-fluoro-benzoyl)indolizin-1-yl]benzoate;
ethyl 4-[3-(2-chloro-6-fluoro-benzoyl)indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichlorobenzoyl)-6-fluoro-indolizin-1-yl]benzoic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2-chloro-6-cyclopropyl-benzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
ethyl 4-[3-(2-chloro-6-cyclopropyl-benzoyl)indolizin-1-yl]-3-fluoro-benzoate;
ethyl 4-[3-(2-chloro-6-cyclopropyl-benzoyl)indolizin-1-yl]benzoate;
ethyl 4-[3-(2-chloro-6-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]benzoate;
ethyl 4-[3-(2-chloro-6-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2-chloro-6-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]benzoic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoic acid;
ethyl 4-[3-(2,6-difluorobenzoyl)indolizin-1-yl]benzoate;
4-[3-(2,6-difluorobenzoyl)indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2,6-difluorobenzoyl)indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-difluorobenzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
[1-(p-tolyl)indolizin-3-yl]-(2,3,6-trifluorophenyl)methanone;
ethyl 3-fluoro-4-[3-(2,3,6-trifluorobenzoyl)indolizin-1-yl]benzoate;
4-[3-(2,3,6-trifluorobenzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]benzoic acid;
3-fluoro-4-[3-(2,3,6-trifluorobenzoyl)indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2,6-difluorobenzoyl)-8-fluoro-indolizin-1-yl]benzoate;
ethyl 4-[3-(2,6-difluorobenzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-difluorobenzoyl)-8-fluoro-indolizin-1-yl]benzoic acid;
4-[3-(2,6-difluorobenzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-8-fluoro-indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2-bromo-6-chloro-benzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2-bromo-6-chloro-benzoyl)indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2,6-dibromobenzoyl)indolizin-1-yl]benzoic acid;
tert-butyl4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-3,6-dihydro-2H-pyridine-1-carboxylate;
tert-butyl 5-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]-3,6-dihydro-2H-pyridine-1-carboxylate;
ethyl 4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]benzoate;
3-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[8-chloro-3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[8-chloro-3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-2-fluoro-benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-8-(trifluoromethyl)indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2,6-dichlorobenzoyl)-8-(trifluoromethyl)indolizin-1-yl]benzoate;
4-[3-(2,6-dichlorobenzoyl)-6-(trifluoromethyl)indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2,6-dichlorobenzoyl)-6-(trifluoromethyl)indolizin-1-yl]benzoate;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
ethyl 4-[3-(2-bromo-6-methyl-benzoyl)indolizin-1-yl]benzoate;
Ethyl 4-[3-(2,6-dichlorobenzoyl)-2-fluoro-indolizin-1-yl]benzoate;
4-[3-(2,6-dichlorobenzoyl)-2-fluoro-indolizin-1-yl]benzoic acid;
methyl 4-[3-(2,6-dichlorobenzoyl)-2-fluoro-indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichlorobenzoyl)-2-fluoro-indolizin-1-yl]-3-fluoro-benzoic acid;
ethyl 4-[3-(2,6-dichloro-3-fluoro-benzoyl)-2-fluoro-indolizin-1-yl]benzoate;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-2-fluoro-indolizin-1-yl]benzoic acid;
ethyl 4-[3-(2,6-dichlorobenzoyl)-2-methyl-indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichlorobenzoyl)-2-methyl-indolizin-1-yl]-3-fluoro-benzoic;
ethyl 4-[3-(2,6-dichlorobenzoyl)-2-methyl-indolizin-1-yl]benzoate;
4-[3-(2,6-dichlorobenzoyl)-2-methyl-indolizin-1-yl]benzoic acid;
4-[3-(2,4-dichloropyridine-3-carbonyl)-2-methyl-indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-2-methyl-indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-2-methyl-indolizin-1-yl]benzoic acid;
methyl 4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-2-methyl-indolizin-1-yl]-3-fluoro-benzoate;
ethyl 4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-2-methyl-indolizin-1-yl]benzoate;
ethyl 4-[3-(2,4-dichloropyridine-3-carbonyl)-2-methyl-indolizin-1-yl]benzoate;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(dimethylcarbamoyl) indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(dimethylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(morpholine-4-carbonyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(piperidine-1-carbonyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(pyrrolidine-1-carbonyl)indolizin-1-yl]benzoic acid;
4-[6-(azetidine-1-carbonyl)-3-(2,6-dichlorobenzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(2-hydroxyethylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(2-methoxyethylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(methylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(4H-1,2,4-triazol-3-yl)indolizin-1-yl]benzoic acid;
4-[6-(azetidine-1-carbonyl)-3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(pyrrolidine-1-carbonyl)indolizin-1-yl]benzoic acid;
4-[6-carbamoyl-3-(2,6-dichlorobenzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(3-methoxyazetidine-1-carbonyl)indolizin-1-yl]benzoic acid;
methyl 4-[3-(2,6-dichlorophenoxy)indolizin-1-yl]-3-fluoro-benzoate;
4-[3-(2,6-dichlorophenoxy)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorophenoxy)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)imidazo[1,5-a]pyridin-1-yl]-N-methyl-benzamide;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]-N,N-dimethyl-benzamide;
[4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]phenyl]-morpholino-methanone;
1-[4-[3-(2,6-dichlorobenzoyl)imidazo[1,5-a]pyridin-1-yl]-3,6-dihydro-2H-pyridin-1-yl]-3,3,3-trifluoro-propan-1-one;
(2,6-dichloro-3-fluoro-phenyl)-[1-(1-ethylsulfonyl-3,6-dihydro-2H-pyridin-5-yl)indolizin-3-yl]methanone;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-5,6,7,8-tetrahydroindolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-2-methyl-5,6,7,8-tetrahydroindolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-5,6,7,8 tetrahydroindolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-5,6,7,8-tetrahydroindolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2-chloro-6-methyl-benzoyl)-5,6,7,8-tetrahydroindolizin-1-yl]benzoic acid;
Sodium 4-[3-(2,6-dichloro-3-fluoro-benzoyl)imidazo[1,5-a]pyridin-1-yl]benzoate;
4-[3-[(2-chloro-6-fluoro-phenyl)methyl]indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]cyclohexanecarboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]cyclohexanecarboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]cyclohexanecarboxylic acid;
1-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]piperidine-4-carboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]cyclohexanecarboxylic acid;
5-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]norbornane-2-carboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]norbornane-1-carboxylic acid;
8-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]spiro[2.5]octane-5-carboxylic acid;
5-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]spiro[2.5]octane-8-carboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-2-hydroxy-cyclohexanecarboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-3-hydroxy-cyclohexanecarboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-5-fluoro-2-hydroxy-benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-8-fluoro-indolizin-1-yl]-5-fluoro-2-hydroxy-benzoic acid;
4-[3-[2-chloro-6-(1-hydroxycyclobutyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-2-fluoro-5-hydroxy-benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(1H-1,2,4-triazol-5-yl)indolizin-1-yl]cyclohexanecarboxylic acid;
4-[3-[(2-chloro-6-methyl-phenyl)methyl]indolizin-1-yl]benzoic acid;
4-[3-[(2,6-dichlorophenyl)methyl]-8-fluoro-indolizin-1-yl]-2-fluoro-benzoic acid;
4-[3-[(2,3,6-trichlorophenyl)methyl]indolizin-1-yl]benzoic acid;
4-[3-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]indolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
1-[3-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]indolizin-1-yl]piperidine-4-carboxylic acid;
(1R)-4-[3-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]indolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
4-[3-[(2,6-dichlorophenyl)-hydroxy-methyl]indolizin-1-yl]benzoic acid;
4-[3-[(2,6-dichlorophenyl)-difluoro-methyl]indolizin-1-yl]benzoic acid;
4-[3-[1-(2,6-dichlorophenyl)-1-methyl-ethyl]indolizin-1-yl]benzoic acid;
4-[3-[1-(2,6-dichlorophenyl)cyclopropyl]indolizin-1-yl]benzoic acid;
4-[3-[3-(2,6-dichlorophenyl)oxetan-3-yl]indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorophenyl)sulfanylindolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorophenyl)sulfonylindolizin-1-yl]benzoic acid;
4-[3-(2,6-dichloroanilino)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichloro-N-methyl-anilino)indolizin-1-yl]benzoic acid;
4-[1-[(2,6-dichlorophenyl)methyl]indolizin-3-yl]benzoic acid;
4-[1-[(2,6-dichlorophenyl)-difluoro-methyl]indolizin-3-yl]benzoic acid;
4-[1-[1-(2,6-dichlorophenyl)cyclopropyl]indolizin-3-yl]benzoic acid;
4-[6-[(2,6-dichlorophenyl)methyl]pyrrolo[1,2-a]pyrimidin-8-yl]benzoic acid;
4-[6-[(2-chloro-6-methyl-phenyl)-difluoro-methyl]pyrrolo[1,2-a]pyrimidin-8-yl]benzoic acid;
6-[6-[1-(2,6-dichlorophenyl)-1-methyl-ethyl]pyrrolo[1,2-a]pyrimidin-8-yl]pyridine-3-carboxylic acid;
6-[6-[1-(2,6-dichlorophenyl)cyclopropyl]pyrrolo[1,2-a]pyrimidin-8-yl]pyridine-3-carboxylic acid;
4-[6-(2,6-dichlorobenzoyl)pyrrolo[1,2-a]pyrimidin-8-yl]benzoic acid;
4-[6-(2,6-dichlorobenzoyl)pyrrolo[1,2-a]pyrazin-8-yl]benzoic acid;
4-[7-(2,6-dichlorobenzoyl)pyrrolo[1,2-c]pyrimidin-5-yl]benzoic acid;
6-[6-(2,6-dichlorophenyl)sulfonylpyrrolo[1,2-a]pyrimidin-8-yl]pyridine-3-carboxylic acid;
4-[6-(2,6-dichlorophenoxy)pyrrolo[1,2-a]pyrimidin-8-yl]benzoic acid;
5-[6-(2,6-dichloroanilino)pyrrolo[1,2-a]pyrimidin-8-yl]pyridine-2-carboxylic acid;
8-(4-carboxyphenyl)-6-(2,6-dichlorobenzoyl)pyrrolo[1,2-a]pyrimidine-3-carboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(morpholine-4-carbonyl)indolizin-1-yl]-2,5-difluoro-benzoic acid;
4-[3-(2,6-difluorobenzoyl)-5,6,7,8-tetrahydroimidazo[1,5-a]yridine-1-yl]cyclohexanecarboxylic acid;
4-[3-(2-chloro-6-methoxy-benzoyl)-5,6,7,8-tetrahydroindolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]cyclohex-3-ene-1-carboxylic acid;
1-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]piperidine-4-carboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-(2-bromo-6-chloro-benzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-5,6,7,8-tetrahydroindolizin-1-yl]-2-fluoro-benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-5,6,7,8-tetrahydroindolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-5,6,7,8-tetrahydroindolizin-1-yl]-2-fluoro-benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]spiro[6,7-dihydro-5H-indolizine-8,1′-cyclopropane]-1-yl]-2-fluoro-benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]spiro[7,8-dihydro-6H-indolizine-5,1′-cyclopropane]-1-yl]-2-fluoro-benzoic acid;
4-[3-(2-Chloro-6-trifluoromethyl-benzoyl)-2-aza-tricyclo[6.1.1.0*2,6*]deca-3,5-dien-5-yl]-2-fluoro-benzoic acid;
4-[3-(3,5-dichloropyridine-4-carbonyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]-1H-imidazole-2-carboxylic acid;
6-[3-(2-chloro-6-cyclopropyl-benzoyl)indolizin-1-yl]pyridine-3-carboxylic acid;
2-[3-(2,6-dichloro-4-fluoro-benzoyl)indolizin-1-yl]pyrimidine-5-carboxylic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)-8-cyano-indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2-chloro-6-fluoro-benzoyl)-5-cyano-indolizin-1-yl]-2-fluoro-benzoic acid;
6-[3-[(2,4,6-trichlorophenyl)methyl]indolizin-1-yl]pyridine-3-carboxylic acid;
5-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]pyrazine-2-carboxylic acid;
4-[6-[2-chloro-6-(trifluoromethyl)benzoyl]pyrrolo [1,2-a]pyrimidin-8-yl]cyclohexanecarboxylic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]spiro[6,8-dihydro-5H-indolizine-7,1′-cyclopropane]-1-yl]benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]benzenesulfonic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]-3-fluoro-benzenesulfonic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-6-(dimethylcarbamoyl)indolizin-1-yl]benzenesulfonic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-5,6,7, 8-tetrahydroindolizin-1-yl]-3-fluoro-benzenesulfonic acid or
4-[3-(2,6-dichloro-3-fluoro-benzoyl)-6-(dimethylcarbamoyl)-5,6,7,8-tetrahydroindolizin-1-yl]benzenesulfonic acid.

### Claim 8 (depends on 1)

A compound of formula (I) as claimed in claim 1 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, which is
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indolizin-1-yl]-3-fluoro-benzoic acid;
4-[3-(2,6-dichloro-3-fluoro-benzoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-8-fluoro-indolizin-1-yl]benzoic acid;
4-[3-[2-bromo-6-(trifluoromethoxy)benzoyl]indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(dimethylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-(2,6-dichlorobenzoyl)-6-(dimethylcarbamoyl)indolizin-1-yl]benzoic acid;
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-6-(pyrrolidine-1-carbonyl)indolizin-1-yl]benzoic acid; or
4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]-5,6,7,8-tetrahydroindolizin-1-yl]benzoic acid.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A pharmaceutical composition comprising at least one compound of formula (I), as claimed in claim 1, or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, together with one or more pharmaceutically acceptable carriers or excipients.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, further comprising at least one additional therapeutically active agent.

### Claim 12 (depends on 1)

A method of treating a retinoic acid-related orphan receptor gamma (RORγ) mediated disease, disorder, syndrome or condition in a subject comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the disease is an inflammatory or autoimmune disease.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the disease, disorder, syndrome or condition is rheumatoid arthritis, psoriasis, systemic lupus erythromatosis, lupus nephritis, scleroderma, chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis, non-radio graphic spondyloarthropathy, chronic pain, acute pain, inflammatory pain, arthritic pain, neuropathic pain, post-operative pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, cancer pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, viral, parasitic or bacterial infection, post-traumatic injury, or pain associated with irritable bowel syndrome.

### Claim 15 (depends on 1)

A method of treating a disease, disorder, syndrome or condition selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, cough, pain, inflammatory pain, chronic pain, acute pain, arthritis, osteoarthritis, multiple sclerosis, rheumatoid arthritis, colitis, ulcerative colitis and inflammatory bowel disease comprising administering to a subject in need thereof a compound according to claim 1.
